Vital et al. found that targeting the AnxA1/FPR2/ALX pathway represents an attractive therapeutic strategy for the treatment of thromboinflammation, counteracting, e.g., stroke in high-risk patient cohorts [34]. Here, FPR2 is linked to stroke disorder.